Fred D. Lublin Explained

Fred D. Lublin is an American neurologist and an authority on the treatment of multiple sclerosis. Along with colleagues at the National Multiple Sclerosis Society, his work redefined the clinical course definitions of MS.^[1]

Lublin is Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center in New York and Saunders Family Professor of Neurology at Mount Sinai School of Medicine. He sits on the board of directors at both the National Multiple Sclerosis Society and MS Hope for a Cure and has been listed in "Who's Who in Frontiers of Science and Technology" and New York Magazine's "Best Doctors" issue every year since 2000.^{[2] [3] [4]}

According to his employer, in 2004, Lublin secured one of the largest grants ever given for MS research, a $25 million grant from the NIH, to study the benefits of combination drug therapy.^[5] He is a consultant to the National Institutes of Health and to pharmaceutical/biotech companies in all phases of drug development in preparation for presentation to the FDA and their advisory panels.

He is the author of numerous scientific publications including Defining the Clinical Course of Multiple Sclerosis: Results of an International Survey, one of the most frequently cited works in the field of multiple sclerosis.^[6]

Biography

Lublin was born in 1946 in Philadelphia, Pa. He graduated from Temple University in 1968 and Jefferson Medical College in 1972. He completed his internship in internal medicine at the Bronx Municipal Hospital, Albert Einstein Medical Center and his residency at the New York Hospital, Cornell Medical Center.

He joined the staff at Mount Sinai Medical Center in April 2000.

Lublin was among the first in the United States to study Interferon β-1b and its ability to treat the relapsing-remitting form of multiple sclerosis; in 1993, IFN β-1b was approved by the U.S. Food and Drug Administration for that very purpose.^[7]

He is the author of nineteen chapters, 136 publications and one text, and is a member of dozens of medical societies including: the National Multiple Sclerosis Society; the MSSM General Clinical Research Center Advisory Committee; and the executive committee of the International Medical & Scientific Board of the Multiple Sclerosis International Federation.

Grants

Partial list:

• Combination Therapy in Multiple Sclerosis, 2003–2012, National Institutes of Health^[8]
• Double-Blind, Placebo-Controlled, 20-Week Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects with Multiple Sclerosis, 2002–Present, Acorda Therapeutics^[9]
• Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV-Chromatography Treatment on Relapses in Patients with Multiple Sclerosis, 2002–Present, Bayer^[10]
• Study to Evaluate IV and Oral Steroids for MS Attacks, 2002–2005, National Multiple Sclerosis Society^[8]
• Study to Evaluate the Preliminary Efficacy, Pharmacokinetics and Immunogenicity of BMS-1 88667 Administered to Subjects with Relapsing-Remitting Multiple Sclerosis, 2001–2003, Bristol-Myers Squibb

Publications

Partial list:

• 8559358 . 46 . Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference . January 1996 . Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS . Neurology . 12–8 . 10.1212/wnl.46.1.12 . 24692780 .
• 8780061 . 46 . Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis . April 1996 . Lublin FD, Reingold SC . Neurology . 907–11 . 10.1212/wnl.46.4.907 . 40213123 .
• 9065528 . 48 . Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: relations between study investigators, advisors, and sponsors. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis . March 1997 . Lublin FD, Reingold SC . Neurology . 572–4 . 10.1212/wnl.48.3.572 . 46647702 .
• 10814796 . 106 . The cellular response of JC virus T-antigen-induced brain tumor implants to a Murine intra-ocular model . July 2000 . Croul S, Lublin FD, Del Valle L . etal . J. Neuroimmunol. . 1–2 . 181–8 . 10.1016/s0165-5728(00)00193-4 . 46109869 .
• 11898526 . 1 . Spectrum and classification of inflammatory demyelinating diseases of the central nervous system . May 2001 . Kalman B, Lublin FD . Curr Neurol Neurosci Rep . 3 . 249–56 . 10.1007/s11910-001-0027-5 . 25496391 .
• 11357961 . 49 . Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS . May 2001 . Lublin FD, Reingold SC . Ann. Neurol. . 677–81 . 10.1002/ana.1025 . 26680369 .
• 12051470 . 39 . Immunotherapy of multiple sclerosis--current practice and future directions . 2002 . Tullman MJ, Lublin FD, Miller AE . J Rehabil Res Dev . 273–85 .
• 12045721 . 15 . The diagnosis of multiple sclerosis . June 2002 . Lublin FD . Curr. Opin. Neurol. . 3 . 253–6 . 10.1097/00019052-200206000-00005 . 29384845 .
• Lublin F.D. . 2002 . Modernize Your Approach to Multiple Sclerosis. . Practical Neurology . 1 . 44–49 .
• 14663037 . 61 . Effect of relapses on development of residual deficit in multiple sclerosis . December 2003 . Lublin FD, Baier M, Cutter G . Neurology . 11 . 1528–32 . 10.1212/01.wnl.0000096175.39831.21 . 9958613 .
• 16170498 . 10.1007/s00415-005-2010-6 . 252 Suppl 3 . History of modern multiple sclerosis therapy . September 2005 . Lublin F . J. Neurol. . iii3–iii9 . 16933337 .
• 16254702 . 10.1007/s00415-005-5008-1 . 252 Suppl 5 . Multiple sclerosis trial designs for the 21st century: building on recent lessons . November 2005 . Lublin F . J. Neurol. . v46–53 . 189867505 .
• 17337274 . 10.1016/j.jns.2007.01.062 . 256 Suppl 1 . The incomplete nature of multiple sclerosis relapse resolution . May 2007 . Lublin FD . J. Neurol. Sci. . S14–8 . 42062273 .
• 18500719 . 10.1002/msj.20030 . 75 . Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies . 2008 . DeAngelis T, Lublin F . Mt. Sinai J. Med. . 2 . 157–67 .
• 18645164 . 10.1212/01.wnl.0000318281.98220.6f . 71 . Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial . July 2008 . Fazekas F, Lublin FD, Li D . etal . Neurology . 4 . 265–71 . 28882940 .

External links

• Mount Sinai Medical Center – About the Corinne Goldsmith Dickinson Center for Multiple Sclerosis
• Mount Sinai School of Medicine
• National Multiple Sclerosis Society (U.S.)
• International Federation of Multiple Sclerosis Societies
• The Multiple Sclerosis Cooperative Research Group
• American Neurological Association
• American Academy of Neurology
• World Federation of Neurology
• International Brain Research Organization
• International Society of Neuroimmunology
• European Charcot Foundation
• Transcript: Fred D. Lublin interview on "Larry King Live"

Notes and References

1. 8780061 . 46 . Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis . April 1996 . Lublin FD, Reingold SC . Neurology . 907–11 . 10.1212/wnl.46.4.907. 40213123 .
2. http://www.nationalmssociety.org/about-the-society/board-of-directors/index.aspx National Multiple Sclerosis Society
3. http://www.mshopeforacure.org/board.php MS Hope for a Cure: Board of Directors
4. http://www.castleconnolly.com/doctors/full.cfm?source=nymetro&doctorID=80CC006124 New York Magazine: Best Doctors, Fred D. Lublin
5. http://www.the-scientist.com/2004/11/22/S34/1/ The Scientist
6. 8780061 . 46 . Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis . April 1996 . Lublin FD, Reingold SC . Neurology . 907–11 . 10.1212/wnl.46.4.907 . 40213123 .
7. http://www.multiplesclerosisprofessional.org/node/47 Multiple Sclerosis Pro – A Resource Center for Clinicians
8. http://clinicaltrials.gov/ clinicaltrials.gov: A Service of the National Institutes of Health
9. http://www.projectsinknowledge.com/cp/1856/index.cfm?thspage=cmeinfo Multiple Sclerosis Management
10. http://www.thisisms.com/article105.html This Is MS: An Unbiased Multiple Sclerosis Community